Below is a full SCF Biomedical Translation Framework application using the Metaphor → Mechanism Conversion Engine applied to Dzogchen (Trekchö + Thögal), generating a multi-omic discovery pathway for:

• Neuro-cognitive disorders
• Vision loss disorders
• Neuro-oncology

This output follows SCF API Discovery logic, multi-omics integration, and FDA-translatable preclinical structuring.

I. SOURCE SYSTEM → BIOMEDICAL TRANSLATION

Ethnomedical Source

• System: Nyingma Dzogchen (Trekchö + Thögal)
• Domain: Consciousness-based non-dual cognition & visionary neuro-perception
• Functional Motifs:
• “Cutting through illusion” (Trekchö)
• “Luminous visionary emergence” (Thögal)

SCF METAPHOR → MECHANISM TRANSLATION TABLE

II. SCF MULTI-OMIC PATHWAY DISCOVERY MAP

1. GENOMICS LAYER

Target Gene Clusters

2. TRANSCRIPTOMICS

Mechanistic Translation

3. PROTEOMICS

Target Protein Systems

4. METABOLOMICS

Energy & Neurochemical Pathways

5. EPIGENOMICS

Regulatory Mechanisms

6. CONNECTOMICS

Circuit-Level Mapping

7. INTERACTOMICS

Network-Level Integration

• Protein–protein interaction stabilization:
• BDNF–TrkB signaling
• PI3K–AKT–mTOR pathway
• Tumor network disruption:
• EGFR inhibition
• VEGF suppression

8. MICROBIOMICS (EXTENDED)

• Gut–brain axis modulation:
• SCFA production → neuroinflammation reduction
• Tryptophan metabolism → serotonin balance

III. THERAPEUTIC TARGET DOMAINS

A. Neuro-Cognitive Disorders

B. Vision Loss Disorders

C. Neuro-Oncology

IV. SCF API DISCOVERY BLUEPRINT (PRECLINICAL)

Candidate Mechanistic Classes

Proposed Multi-Compound Synergy Stack (SCF Fibonacci Model)

V. NOVEL MOLECULAR MECHANISM HYPOTHESES

1. “Rigpa-State Neural Coherence Mechanism”

• Gamma synchrony induction
• DMN suppression
• Network-wide entropy reduction

2. “Tigle Photonic Signaling Axis”

• Biophoton emission in retinal–cortical pathways
• Light-mediated intracellular signaling
• Potential role in:
• Neuroregeneration
• Visual restoration

3. “Trekchö Synaptic Pruning Mechanism”

• Selective elimination of dysfunctional synapses
• Restoration of:
• Signal-to-noise ratio
• Cognitive clarity

4. “Thögal Hyper-Integration Cascade”

• Enhanced cross-network connectivity
• Activation of:
• Visual cortex
• Associative cortex
• Potential application:
• Neurodegeneration reversal
• Sensory restoration

VI. TRANSLATIONAL DEVELOPMENT PATHWAY (FDA-ALIGNED)

Preclinical Phase

• In vitro:
• Neuronal cultures (BDNF, synaptic density)
• Retinal organoids (photoreceptor survival)
• Glioma cell lines (proliferation inhibition)
• In vivo:
• Alzheimer’s mouse models
• Retinal degeneration models
• Glioblastoma xenografts

IND-Enabling Studies

• PK/PD profiling
• BBB penetration validation
• Toxicology (multi-organ)

Clinical Endpoints

(Fully aligned with FDA pathways  )

VII. CONCLUSION

Using SCF Biomedical Translation:

• Dzogchen metaphors → multi-omic therapeutic targets
• Trekchö → network pruning & cognitive reset
• Thögal → photonic-neural integration & regeneration

This yields novel drug discovery pathways spanning:

• Neurodegeneration
• Vision restoration
• Neuro-oncology

with strong alignment to multi-target, high-barrier, low-toxicity SCF therapeutic design principles  .

MASTER REGISTRY INDEX

• SCF-BMT-DZOG-NEURO-0001 — Dzogchen Biomedical Translation (Neuro Systems)
• SCF-MULTIOMIC-DISC-0004 — Multi-Omic Therapeutic Discovery Map
• SCF-API-NEUROVIS-ONCO-0007 — Neuro–Vision–Oncology API Blueprint
• SCF-TRANSL-FDA-0002 — FDA-Aligned Translational Development Framework